104 related articles for article (PubMed ID: 9123690)
21. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
Shimabukuro T; Nakamura K; Uchiyama K; Tei Y; Aoki A; Naito K
Hinyokika Kiyo; 2006 Feb; 52(2):99-105. PubMed ID: 16541762
[TBL] [Abstract][Full Text] [Related]
22. [Bladder cancer chemotherapy practice study].
Clippe C; Clippe S; Yzebe D; Flechon A; Droz JP
Prog Urol; 2002 Sep; 12(4):609-14. PubMed ID: 12463119
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
Calabrò F; Sternberg CN
Eur Urol; 2009 Feb; 55(2):348-58. PubMed ID: 18977070
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
[TBL] [Abstract][Full Text] [Related]
25. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
deVere White RW; Katz MH; Steinberg GD
J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
[No Abstract] [Full Text] [Related]
26. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
Rosenberg JE
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1729-36. PubMed ID: 18062747
[TBL] [Abstract][Full Text] [Related]
27. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
[TBL] [Abstract][Full Text] [Related]
28. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy in invasive bladder cancer.
Bamias A; Dimopoulos MA
Expert Rev Anticancer Ther; 2005 Dec; 5(6):993-1000. PubMed ID: 16336090
[TBL] [Abstract][Full Text] [Related]
30. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival.
Bellmunt J; Hautmann RE
Eur Urol; 2008 Nov; 54(5):1192-7. PubMed ID: 18707804
[No Abstract] [Full Text] [Related]
31. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
Ruggeri EM; Giannarelli D; Bria E; Carlini P; Felici A; Nelli F; Gallucci M; Cognetti F; Pollera CF
Cancer; 2006 Feb; 106(4):783-8. PubMed ID: 16419069
[TBL] [Abstract][Full Text] [Related]
32. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
33. The current status of adjuvant chemotherapy for bladder cancer.
Tannock IF
Semin Urol; 1990 Nov; 8(4):291-7. PubMed ID: 2284534
[No Abstract] [Full Text] [Related]
34. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
35. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
[TBL] [Abstract][Full Text] [Related]
37. Bladder cancer clinical trials.
Lerner SP
Urol Oncol; 2005; 23(4):275-9. PubMed ID: 16018944
[TBL] [Abstract][Full Text] [Related]
38. Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Sylvester RJ
Eur Urol; 2008 May; 53(5):1002. PubMed ID: 17950990
[No Abstract] [Full Text] [Related]
39. Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2009 Feb; 55(2):303-5; discussion 305-6. PubMed ID: 18995950
[No Abstract] [Full Text] [Related]
40. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
